These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28226402)

  • 1. Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View.
    Lemaitre F; Tron C; Rayar M
    Am J Transplant; 2017 Jun; 17(6):1691-1692. PubMed ID: 28226402
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View".
    Tremblay S; Nigro V; Woodle ES; Alloway RR
    Am J Transplant; 2017 Jun; 17(6):1693. PubMed ID: 28248455
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of low-dose calcineurin inhibitor regimens in pediatric kidney transplantation.
    Chambers ET
    Am J Transplant; 2021 Jan; 21(1):11-12. PubMed ID: 32580235
    [No Abstract]   [Full Text] [Related]  

  • 6. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.
    Press RR; de Fijter JW; Guchelaar HJ
    Curr Pharm Des; 2010; 16(2):176-86. PubMed ID: 20205663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapatient variability in solid organ transplantation: Should we make the first move earlier?
    Lemaitre F; Tron C; Jezequel C; Verdier MC; Rayar M
    Am J Transplant; 2019 Feb; 19(2):610. PubMed ID: 30188607
    [No Abstract]   [Full Text] [Related]  

  • 8. Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.
    Greenland JR; Chong T; Wang AS; Martinez E; Shrestha P; Kukreja J; Hays SR; Golden JA; Singer JP; Tang Q
    Am J Transplant; 2018 Aug; 18(8):2043-2049. PubMed ID: 29673076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.
    McCune JS; Bemer MJ
    Clin Pharmacokinet; 2016 May; 55(5):525-50. PubMed ID: 26563168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
    de Jonge H; Naesens M; Kuypers DR
    Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
    Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
    Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gingival hypertrophy in a kidney transplant recipient.
    Mabrouk A; Tamzali Y; Barrou B; Tourret J
    Am J Transplant; 2022 Sep; 22(9):2273-2275. PubMed ID: 36039542
    [No Abstract]   [Full Text] [Related]  

  • 15. Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients.
    Erro R; Bacchin R; Magrinelli F; Tomei P; Geroin C; Squintani G; Lupo A; Zaza G; Tinazzi M
    J Neurol; 2018 Jul; 265(7):1676-1683. PubMed ID: 29777361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation.
    Sikma MA; Hunault CC; Huitema ADR; De Lange DW; Van Maarseveen EM
    Clin Pharmacokinet; 2020 Apr; 59(4):403-408. PubMed ID: 31820394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitors nephrotoxicity revisited.
    Pallet N
    Am J Transplant; 2021 Sep; 21(9):2929-2930. PubMed ID: 33797862
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
    Utecht KN; Hiles JJ; Kolesar J
    Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2 receptor engineering enhances regulatory T cell function suppressed by calcineurin inhibitor.
    Hirai T; Lin PY; Ramos TL; Simonetta F; Su LL; Picton LK; Baker J; Lohmeyer JK; Garcia KC; Negrin RS
    Am J Transplant; 2022 Dec; 22(12):3061-3068. PubMed ID: 36031344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
    Prytuła A; van Gelder T
    Pediatr Nephrol; 2019 Jan; 34(1):31-43. PubMed ID: 29479631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.